Statement of Principles concerning hypothyroidism (Balance of Probabilities) (No. 4 of 2022)

The Statement organises the legal-medical causation inquiry around three core concepts: the definition and scope of hypothyroidism, the enumerated causal factors, and the relationship of those factors to relevant service.

Definition and scope of hypothyroidism: The instrument defines hypothyroidism as a functional disorder with deficiency of thyroid hormone producing clinical symptoms or warranting medical treatment (s 7(2)(a)). It expressly includes primary, central and peripheral hypothyroidism (s 7(2)(b)(i)-(iii)). It excludes congenital hypothyroidism, congenital iodine-deficiency syndrome, Hashimoto thyroiditis, sick euthyroid syndrome, subclinical hypothyroidism and transient hypothyroidism during recovery from non-thyroidal illness (s 7(2)(c)(i)-(vi)). Notes in s 7 explain typical biochemical findings and clinical symptoms and state that when hypothyroidism is a manifestation of Hashimoto thyroiditis, the Hashimoto Statements of Principles apply (s 7 note 3).

Death: The definition of hypothyroidism is extended to include death from a terminal event or condition contributed to by the person’s hypothyroidism (s 7(3)). The Schedule defines terminal event and provides examples such as pneumonia and cardiac arrest (Schedule 1: terminal event).

Enumerated causal factors: Section 9 contains a comprehensive list of factors, each of which, if present and related to relevant service, is sufficient to meet the Statement’s medical test. The factors are expressed as temporal exposure windows and specific conditions. They cover iodine deficiency and excess, administration of iodine-containing contrast agents, exposure to a specified list of drugs, iodine-containing drugs at defined doses and durations, amiodarone with a distinct time window, pregnancy and the 12 months postpartum, specified forms of thyroiditis, therapeutic radiation where the thyroid was in the field, radioactive iodine (iodine‑131) treatment, thyroid surgery, specified thyroid diseases and neoplasms, hypopituitarism with TSH deficiency, long-term obesity, acute precipitating events for myxoedema coma, and inability to obtain appropriate clinical management (s 9(1)-(36)).

Temporal structure: The causal factors are framed for two clinical states. Subsections 9(1)-9(17) are directed at the clinical onset of hypothyroidism. Subsections 9(18)-9(36) are directed at clinical worsening of hypothyroidism. Section 10(2) clarifies that the latter group (9(18)-9(36)) applies only to material contribution or aggravation where the person’s hypothyroidism pre‑existed service or was suffered or contracted before or during (but did not arise out of) the person’s relevant service.

Quantified definitions and thresholds: The Schedule turns clinical language into quantifiable thresholds. For example, iodine deficiency is an average intake of less than 150 micrograms per day for adults for at least 30 continuous days, or urinary iodine concentration less than 100 micrograms per litre (Schedule 1). Iodine excess uses adult thresholds of more than 1,100 micrograms per day over three months or urinary iodine concentration greater than 300 micrograms per litre (Schedule 1). Being obese is a BMI of 30 or greater (Schedule 1). The specified list of drugs and diseases are enumerated in the Schedule.

Cross-reference mechanism: Section 11 provides a mechanism to import other Statements of Principles where a factor refers to an injury or disease already the subject of another Statement. That other Statement “applies in accordance with the terms of that Statement of Principles as in force from time to time” (s 11).

Standard of proof and medical basis: The Authority states the medical-scientific basis in s 8, asserting its view that it is “more probable than not” that hypothyroidism and death from hypothyroidism can be related to relevant service. The title reinforces the standard of proof as balance of probabilities.

Primary individuals affected by this Statement are persons who make claims under the statutory schemes referenced in the instrument: claims “to which section 120B of the VEA or section 339 of the MRCA applies” (s 5). The instrument does not itself grant benefits; it prescribes the medical causation framework decision-makers must apply when considering entitlement under those claim provisions. Consequently the practical set of affected people is claimants (veterans and members of the Forces whose service falls within the Schedule’s definition of relevant service), their legal and medical advisers, and adjudicators processing claims under the VEA and MRCA.

Relevant service is defined in the Schedule as eligible war service (other than operational service) under the VEA, defence service (other than hazardous service and British nuclear test defence service) under the VEA, or peacetime service under the MRCA (Schedule 1: relevant service). Therefore the Statement applies to claims arising from those service categories; it does not purport to apply to other classes of service or civilians beyond the statutory scope.

Medical practitioners who provide expert opinions for Veterans’ Affairs claims will be practically affected because the Statement sets the clinical constructs and thresholds adjudicators will apply. For example, clinicians must be able to document exposures that fall within the precise time windows and quantitative thresholds in s 9 and Schedule 1, such as average iodine intake, urinary iodine concentration, duration and timing of drug exposure, amiodarone duration parameters, pregnancy and postpartum timing, radiotherapy fields, radioactive iodine treatment, thyroidectomy documentation, and BMI history.

Decision-makers in Veterans’ Affairs and MRCA claims processing are affected because the Statement is the Authority’s determination under s 196B(3) of the VEA and thus forms the medical-scientific position for causation assessments (s 3; s 8). Where a factor in s 9 refers to an injury or disease covered by another Statement, decision-makers must consult that other Statement and apply it as in force from time to time (s 11). The repealed 2013 Statement is expressly revoked by s 4; decision-makers and advisers must rely on this current instrument for claims commencing after its commencement date (s 2).

Third parties who may be involved in evidentiary collection are also implicated. For example, radiology providers, pharmacists, hospitals, surgical services and pathology laboratories may be asked for records that establish the timing and nature of contrast administration, medication histories, operative reports for thyroidectomy or neck surgery, radiation field documentation, urinary iodine results, and thyroid hormone assays. Where hypothyroidism manifests as a terminal contribution to death, coronial or death records that list terminal events such as pneumonia or respiratory failure may be relevant (Schedule 1: terminal event).

Finally, the instrument affects other Statement authors and administrators because s 11 mandates interplay where factors refer to injuries covered by other Statements. That creates an operational dependency across Statements of Principles.

The Statement itself does not create statutory rights of entitlement or specific duties in the sense of criminal or civil obligations. It is a determinative medical instrument whose duty-like effect is to guide adjudicators in applying the VEA and MRCA claim provisions. Key operative obligations and rights that follow from the text are therefore procedural and evidentiary.

Duty to relate factors to relevant service. A claimant must show that at least one of the enumerated factors in section 9 exists and that it is related to the claimant’s relevant service (s 9; s 10(1)). The Statement requires a causal nexus between a listed factor and the person’s relevant service; the factor alone is not sufficient unless it is shown to be related to service.

Temporal and pre-existence rules. For clinical worsening factors (subsections 9(18)-9(36)), the Statement provides that those factors apply only to material contribution to, or aggravation of, hypothyroidism “where the person's hypothyroidism was suffered or contracted before or during (but did not arise out of) the person's relevant service” (s 10(2)). That creates a distinct evidential obligation: when relying on subsections 9(18)-9(36) a claimant must establish that hypothyroidism pre‑existed service or was suffered or contracted before or during service, and that the listed factor materially contributed to aggravation.

Obligation to consider cross-referenced Statements. Section 11 requires that where a factor in section 9 refers to another injury or disease that is covered by a different Statement of Principles, that other Statement “applies in accordance with the terms of that Statement of Principles as in force from time to time.” This places a duty on decision-makers and advisers to consult and apply other Statements when relevant. For claimants, it imposes an evidentiary duty to marshal the records and clinical findings that those other Statements require.

Standards for clinical definitions and exposures. The Schedule provides quantitative and clinical thresholds that are to be used for assessing whether the defining conditions are met. These thresholds convert clinical facts into claim-relevant criteria: for example, iodine deficiency and iodine excess are defined by average intake and urinary iodine levels over specified durations, being obese is defined by BMI ≥30, and myxoedema coma has a clinical description. Those thresholds impose practical duties on parties to supply medical records, laboratory results and histories that fit those numerical criteria.

Right to have causation assessed on the balance of probabilities. The Statement records the Authority’s view “on the sound medical‑scientific evidence available” that it is more probable than not that hypothyroidism and death from hypothyroidism can be related to relevant service (s 8). The Statement is titled “Balance of Probabilities”, signalling that the causation assessment derived from the Statement uses that civil standard.

Duty to apply the instrument in claims covered by s 120B of the VEA or s 339 of the MRCA. The instrument expressly applies to claims to which those provisions apply (s 5). Decision-makers and claimants must therefore situate the Statement within the procedural context of those claim provisions.

No criminal penalties or express enforcement measures in the instrument. The Statement contains no penalty provisions; it is a medico-legal template for causation in claims rather than a regulatory instrument that imposes fines or criminal sanctions.

The Statement itself contains no penalties, infringement mechanisms or criminal sanctions. It is a medical determinative instrument made under subsection 196B(3) of the Veterans' Entitlements Act 1986 and operates as the Repatriation Medical Authority’s medical-scientific view for causation (s 3; s 8). It does not, on its face, create enforcement powers or sanctions for non-compliance by claimants, health practitioners, or third parties.

Enforcement in practice is exercised through the administrative decision-making processes established under the VEA and the MRCA. The Statement applies to claims within the scope of section 120B of the VEA and section 339 of the MRCA (s 5). Those Acts set out the entitlement and procedural frameworks, including decision-making, review and appeals, and any remedial consequences if a claim is accepted or rejected, but those procedural and enforcement provisions are not reproduced in this instrument. The Statement’s role is evidentiary: it supplies the medical causation criteria that decision-makers apply when determining whether an accepted causal link exists under the VEA/MRCA claim provisions.

There is no provision in the instrument that imposes record-keeping fines, compels production of documents, or creates inspection powers. If a claimant cannot produce evidence to establish a factor in s 9, the consequence is that the medical test under the Statement will not be satisfied, which may lead to denial of a claim under the VEA/MRCA processes. That practical consequence, however, is a procedural outcome governed by the administering Acts, not by the Statement itself.

The Statement does not set standards of professional conduct for clinicians beyond the need to supply medically credible evidence. It will, however, influence the content of expert medical opinions because adjudicators will measure those opinions against the definitions, time windows and enumerated lists in section 9 and Schedule 1.

Finally, Section 11 requires that if a factor mentioned in section 9 refers to an injury or disease that is covered by another Statement of Principles, then that other Statement applies “as in force from time to time” (s 11). This produces an ongoing compliance and interpretive obligation for decision-makers to consult and apply up-to-date Statements. The instrument provides no separate enforcement mechanism to ensure that such cross-reference occurs; compliance will be implemented through the adjudicative machinery of the VEA and MRCA.

The Statement is an instrument made under subsection 196B(3) of the VEA (s 3) and explicitly applies to claims to which section 120B of the VEA or section 339 of the MRCA applies (s 5). Hence its interaction with other laws is primarily functional: it supplies the Repatriation Medical Authority’s medical tests to be used within the statutory claim frameworks of the VEA and the MRCA.

Cross-reference to other Statements of Principles. Section 11 creates a formal mechanism for interaction across Statements of Principles. If a factor in section 9 refers to an injury or disease that is the subject of a different Statement determined under s 196B(3) of the VEA, then that other Statement “applies in accordance with the terms of that Statement of Principles as in force from time to time” (s 11). Practically, this means that adjudicators must consult the current text of other Statements where, for example, a factor invokes a form of thyroiditis or a disease such as sarcoidosis, which are covered by other Statements. This produces a dynamic legal relationship between Statements rather than isolation; changes to other Statements may alter how a factor is applied in hypothyroidism claims.

Interaction with the VEA and MRCA frameworks. The instrument does not restate the entitlements, procedural rights, review pathways or merits and judicial review rules contained in the VEA or MRCA. Those Acts determine who may apply, the types of compensable conditions, and the remedies available. The Statement provides the medical causation criteria that must be applied within those statutory schemes. For example, the reference to specific claim provisions (s 5) shows that the Statement must be read in combination with the procedures and legal tests those provisions contain.

Repeal of prior Statement and continuity. Section 4 repeals the 2013 Statement (Statement No. 30 of 2013), which had been made under subsections 196B(3) and (8) of the VEA. The repeal indicates that the present instrument supersedes the previous one for the purposes of claims after commencement. Administrative bodies and advisers must therefore use the present instrument once it commenced on 31 January 2022 (s 2). The repeal changes the applicable medical framework and means that any reliance on the 2013 Statement must be revisited.

Interaction with clinical and evidential standards. The Schedule supplies quantitative thresholds (eg iodine intake, urinary iodine concentrations, BMI). Those numerical tests interact with medical standards and laboratory reporting; for claims purposes, adjudicators will interpret clinical records and lab results against these statutory thresholds rather than against a generic clinical standard. That interaction makes the Statement a bridge between clinical evidence and statutory causation tests.

No express conflict-override clauses. The Statement does not contain provisions that purport to override other substantive laws. Its application is expressly limited to claims under the cited provisions of the VEA and MRCA (s 5), and where it refers to other Statements, those Statements govern the referred aspects (s 11). Any conflict between the Statement and other legal instruments would be resolved in accordance with the usual rules of statutory interpretation and the primacy of the Acts under which claims are made, but the instrument itself does not provide a hierarchy beyond its cross-reference rule.

This instrument is identified as the Statement of Principles concerning hypothyroidism (Balance of Probabilities) (No. 4 of 2022) and is dated 24 December 2021 (front matter and signature). The instrument commences on 31 January 2022 (s 2). Section 4 expressly repeals the prior Statement of Principles concerning hypothyroidism No. 30 of 2013 (Federal Register of Legislation No. F2013L00730), which had been made under subsections 196B(3) and (8) of the VEA. The instrument itself is made under subsection 196B(3) only (s 3). Those are the express historical and textual events recorded in the instrument.

The Schedule’s definitions and the enumerated factors in section 9 constitute the substance of the amendment from the prior instrument. The present instrument republishes and re‑packages the causal factors, definitions and exclusions. The instrument’s s 11 clause anticipates ongoing changes to other Statements by providing that where a factor refers to another injury or disease for which a Statement exists, that Statement applies “as in force from time to time.” That language implicitly recognises that Statements of Principles are periodically revised and that their interactions will be subject to subsequent amendments.

There is no further amendment record inside the instrument. The instrument does not list prior amendments to the 2013 Statement, nor does it include a schedule of changes between the two Statements. It records the repeal of the 2013 instrument and replaces it with this instrument, which became the operative Statement upon commencement.

For practitioners and administrators, the key amendment history facts they must note are: (1) the 2013 Statement has been repealed (s 4); (2) this new Statement commenced on 31 January 2022 (s 2); and (3) it is made under s 196B(3) (s 3). Any decisions or claims that fall after commencement should therefore be assessed using this instrument rather than the 2013 instrument.

Because s 11 allows other Statements “as in force from time to time” to be imported when a factor refers to another disease, the practical amendment history of how hypothyroidism causation is applied may change over time as other Statements are amended. Users of the Statement should therefore check the current versions of any cross-referenced Statements when preparing or determining claims.

The text of this instrument contains no references to judicial proceedings, decisions, or litigation related to the Statement. It does not cite cases and it does not summarise any legal challenges to prior or current Statements. The instrument is a determinative medical statement issued by the Repatriation Medical Authority under statutory power; as such, any litigation concerning its application, validity, or interpretation would occur in the context of proceedings under the VEA or MRCA, or in review of administrative decisions that applied the Statement. None of those proceedings are recorded in this instrument.

Practitioners seeking reported litigation that tests the content, application, or legal effect of this or earlier hypothyroidism Statements would need to search external judicial databases and decisions under the VEA/MRCA schemes. This instrument, however, makes no reference to such cases and contains no judicial annotations or interpretative guidance deriving from litigation.

Because s 11 permits cross-reference to other Statements “as in force from time to time,” litigation concerning other Statements could have indirect relevance to claims involving hypothyroidism where those other Statements are imported under s 11. Again, that consequence is not reflected in the instrument itself and would need to be traced by examining external case law.

In short, the instrument documents no litigation history. Any assertion about how courts have interpreted these provisions or prior Statements would require independent case-law research outside the four corners of this instrument.

This Statement contains a number of technical features and precise thresholds that are operationally consequential for claim preparation and adjudication. Identifying these features avoids common pitfalls for advisers, clinicians and decision-makers.

1. Different time-windows for onset versus worsening. Section 9 is split between factors that relate to clinical onset (subsections 9(1)-9(17)) and factors that relate to clinical worsening (subsections 9(18)-9(36)). Importantly, subsection 10(2) restricts the application of the worsening factors to situations where hypothyroidism was suffered or contracted before or during (but did not arise out of) the person’s relevant service and where the factor materially contributes to or aggravates the condition. Practically, advisers must be careful to map the clinical event (onset versus worsening) and the chronology against these separate lists.

2. Exclusions that can be counter-intuitive. The Statement excludes Hashimoto thyroiditis from the definition of hypothyroidism (s 7(2)(c)(iii)), but Note 3 to s 7 clarifies that when hypothyroidism is a clinical manifestation of Hashimoto thyroiditis, it is covered by the Hashimoto Statements of Principles. The practical effect is that a claimant whose hypothyroidism results from Hashimoto must look to the Hashimoto Statements, not this instrument, for causation criteria. Subclinical hypothyroidism is also excluded (s 7(2)(c)(v)), so biochemical or marginally abnormal thyroid function tests without clinical symptoms or treatment may not meet the threshold.

3. Numeric thresholds for iodine. Iodine deficiency and iodine excess are defined quantitatively in the Schedule, with different numeric thresholds for pregnant women (Schedule 1: iodine deficiency; iodine excess). For example, iodine deficiency for adults is an average intake below 150 micrograms per day for at least 30 days, or urinary iodine concentration below 100 micrograms per litre; for pregnant women the thresholds are higher (Schedule 1). Iodine excess uses an adult threshold of more than 1,100 micrograms per day over three months or urinary iodine greater than 300 micrograms per litre. Claims relying on iodine data must therefore produce intake records or urinary iodine results that meet these numerical criteria. General statements about “iodine exposure” without measured intake or urinary levels will be vulnerable.

4. Drug exposure lists and differing temporal parameters. The Schedule enumerates the specified list of drugs (Schedule 1: specified list of drugs). Some factors use a 3‑month window before clinical onset/worsening for exposure to drugs from that list (s 9(4); s 9(21)). Separate rules apply for drugs containing at least 10 mg iodine daily for a continuous period of at least 4 weeks within 3 months (s 9(5); s 9(22)). Amiodarone has a distinct requirement of continuous use for at least 2 weeks within the 1 year before clinical onset or worsening (s 9(6); s 9(23)). Those different temporal and dosage rules are granular and must be matched precisely to pharmacy and medical records.

5. Pregnancy and postpartum timing. Pregnancy or being within the 12 months postpartum at clinical onset or worsening is a listed factor (s 9(7); s 9(25)). Accurate obstetric records and exact dates are therefore necessary to show this factor applies.

6. Surgical and radiotherapy exposures require anatomical specificity. Factors for therapeutic radiation, iodine‑131 treatment, subtotal or total thyroidectomy or neck surgery specify that the thyroid gland must have been in the field of radiation or involved in the surgery (s 9(9)-(11); s 9(27)-(29)). Operative reports and radiation field documentation must therefore specify the involvement of the thyroid; generic statements that “the patient had neck surgery” without detailing thyroid involvement may not suffice.

7. Myxoedema coma has particular triggers and limited windows. For hypothyroidism presenting as myxoedema coma, subsection 9(17) requires an acute precipitating event within 48 hours before clinical onset; similarly for worsening under subsection 9(35). The Schedule defines acute precipitating events and lists many examples including abrupt cessation of thyroxine, acute illness, certain drugs and hypothermia. Timing is crucial here; the examiner must document the precipitating event within the 48‑hour window.

8. Obesity requires a 5‑year history. The instrument treats being obese for at least 5 years before onset or worsening as a factor (s 9(16); s 9(34)). This is not a snapshot BMI; it requires a sustained history of BMI ≥30 (Schedule 1). Historical weight records are therefore relevant.

9. “Inability to obtain appropriate clinical management” is open-ended. Subsection 9(36) recognises inability to obtain appropriate clinical management for hypothyroidism as a factor for clinical worsening. The instrument provides no numeric threshold or definition for what constitutes “appropriate clinical management.” This creates an evidentiary gap that will require a contextual medical assessment and documentary material showing access limitations, treatment refusals, geographic or service-related barriers.

10. Cross-application to other Statements. A factor in section 9 may refer to another disease for which a Statement exists; s 11 then imports and applies that Statement. Practitioners must identify whether any listed factor references such other diseases (for example certain forms of thyroiditis or specified diseases like sarcoidosis) and then consult the current text of the other Statements.

11. Death defined as contribution to terminal events. Section 7(3) extends “hypothyroidism” to include death from a terminal event contributed to by hypothyroidism. The Schedule’s terminal event list is non-exhaustive in form but gives examples such as pneumonia and circulatory failure. Coroners’ reports or death certificates listing these terminal events may therefore be relevant evidence, but causation requires showing hypothyroidism contributed to those terminal events.

12. Exclusions for congenital and transient conditions. Congenital hypothyroidism and transient hypothyroidism during recovery from non-thyroidal illness are excluded (s 7(2)(c)(i),(vi)). Where onset is neonatal or clearly transient in context of another illness the instrument will not apply.

These technicalities translate into practical evidentiary and procedural risks. Failure to map clinical events to the section 9 factor structure, to meet the Schedule’s numeric thresholds, or to provide documentary proof of timing and anatomical involvement will make causation under this Statement harder to establish.

For claimants, medical advisers and decision-makers the Statement prescribes precise evidentiary steps and mapping exercises. Below are concrete actions and documentary sources that align to the instrument’s structure.

1. Identify the clinical event: onset or worsening. First, determine whether the claim concerns clinical onset of hypothyroidism or the clinical worsening of pre-existing hypothyroidism. This determines which subsections of section 9 are relevant (s 9(1)-(17) for onset; s 9(18)-(36) for worsening) and whether subsection 10(2) (pre‑existence requirement) applies.

2. Establish relevant service. Confirm that the claimant’s service qualifies as “relevant service” under the Schedule: eligible war service (other than operational service), defence service (other than hazardous service and British nuclear test defence service) under the VEA, or peacetime service under the MRCA (Schedule 1: relevant service). This determines whether the Statement applies to the claim (s 5).

3. Map to at least one section 9 factor. Review the enumerated factors in s 9 and select the factor(s) that best align with the claimant’s clinical history. Common evidence required:

   • Iodine deficiency or excess (s 9(1), 9(2), 9(18), 9(19)). Produce documentary evidence of average iodine intake (dietary histories, supplement records) showing amounts and duration, or urinary iodine concentration results from clinical laboratories that meet the Schedule numeric thresholds (Schedule 1: iodine deficiency; iodine excess). For pregnant or lactating women, use the higher thresholds specified in the Schedule.

   • Iodine-containing radiographic contrast (s 9(3), 9(20)). Provide radiology records and contrast administration notes showing the agent and date within the 3‑month window.

   • Drugs from the specified list (s 9(4), 9(21)). Supply prescription records, pharmacy dispensing records, hospital medication charts with dates demonstrating use within the relevant 3‑month window. Compare the specific drug to the Schedule list.

   • Drugs containing ≥10 mg iodine daily for 4 continuous weeks within 3 months (s 9(5), 9(22)). Provide dosage documentation, formulation details and continuous administration records.

   • Amiodarone (s 9(6), 9(23)). Provide cardiology records and dispensing history showing continuous use for at least 2 weeks within the year prior to onset/worsening.

   • Pregnancy/postpartum (s 9(7), 9(25)). Provide obstetric records with dates of pregnancy and delivery to show the 12‑month postpartum window.

   • Forms of thyroiditis and specified diseases (s 9(8), 9(26), 9(12), 9(30)). Produce histopathology, serology, imaging and specialist reports that diagnose the specific form as listed in the Schedule; if a listed form is covered by another Statement, then obtain the findings required by that Statement because s 11 requires applying that other Statement.

   • Therapeutic radiation or iodine‑131 (s 9(9), 9(10), 9(27), 9(28)). Supply radiotherapy treatment plans and field charts or nuclear medicine therapy records showing the thyroid was in the radiation field or that iodine‑131 treatment occurred before onset/worsening.

   • Thyroidectomy or neck surgery (s 9(11), 9(29)). Provide operative reports, pathology and hospital discharge summaries that specify thyroid removal or surgical involvement.

   • Malignancy and neoplasms (s 9(13), 9(31), 9(14), 9(32)). Supply oncology records, histopathology and specialist letters.

   • Hypopituitarism with TSH deficiency (s 9(15), 9(33)). Provide endocrinology assessments, pituitary imaging and laboratory results showing TSH deficiency.

   • Obesity for at least 5 years (s 9(16), 9(34)). Compile weight records over a multi‑year period, occupational health records, GP notes and measurements establishing BMI ≥30 for a continuous 5‑year period.

   • Myxoedema coma (s 9(17), 9(35)). Document the acute precipitating event within 48 hours, acute hospital notes, ICU records and biochemical evidence of severe hypothyroxinaemia and clinical signs consistent with the Schedule’s definition.

   • Inability to obtain appropriate clinical management (s 9(36)). Provide evidence of attempted access to care, service-related barriers, correspondence with health services, and contemporaneous notes showing treatment gaps and their causes.

4. Link the factor to relevant service. For each selected factor, provide evidence that the exposure or condition was related to the person’s relevant service. This may require service records, deployment medical records, medication administration records while in service, surgical or radiotherapy undertaken in service, or evidence that service conditions produced iodine exposure or deprivation.

5. Meet Schedule numeric and definitional tests. Where the Schedule provides quantitative thresholds (iodine intake, urinary iodine, BMI), ensure that laboratory reports and clinical histories are produced to match those thresholds (Schedule 1). Arbitrary or approximate statements are unlikely to meet the instrument’s test.

6. Address exclusions. If the clinical picture could fall within an exclusion (congenital hypothyroidism, Hashimoto, subclinical hypothyroidism, transient hypothyroidism during recovery), either demonstrate that the condition is outside the exclusion or, if Hashimoto is involved, prepare to rely on the Hashimoto Statements of Principles in accordance with s 11 and the Note to s 7.

7. Cross-check other Statements. Where a chosen factor refers to another disease (eg systemic lupus erythematosus, sarcoidosis) check the current Statements of Principles relating to those diseases because s 11 requires applying those Statements “as in force from time to time.” Obtain the evidence those Statements require.

8. Prepare expert medical opinion aligned to the Statement. Medical experts should frame their opinions to address each legal element the Statement sets out: (a) confirm the diagnosis of hypothyroidism in accordance with s 7(2)(a); (b) identify which s 9 factor(s) are present, reference the Schedule definitions and thresholds, and verify timing; (c) give an opinion on whether the factor was related to relevant service (s 10(1)); and where applicable, for subsections 9(18)-9(36), opine on material contribution or aggravation consistent with s 10(2). Opinions should use the “more probable than not” standard consistent with the Statement’s framing (s 8).

9. Document deaths that are alleged to result from hypothyroidism. If death is alleged to be from hypothyroidism, produce the death certificate, coronial report if any, hospital notes and evidence showing that hypothyroidism contributed to the terminal event identified in the Schedule (s 7(3); Schedule 1: terminal event).

10. Keep contemporaneous records and service evidence. Because many causation factors are time‑sensitive, contemporaneous service medical records, pharmacy records, radiology and operative reports are often decisive. Delays in obtaining or preserving those records create practical risk.

11. For decision‑makers, check for repeal and currency. Confirm that this Statement is the operative instrument for the claim period (s 2; s 4). If a factor refers to another Statement, ensure that the current version of that other Statement is applied (s 11).

12. Prepare to explain subjective or open-ended factors. For items such as “inability to obtain appropriate clinical management” (s 9(36)) expect to explain the nature of the lack of access, the causal pathway to worsening, and contemporaneous attempts to obtain care.

Following these steps ensures that evidentiary preparation and expert opinion align with the Statement’s text, numeric thresholds and temporal windows, and helps avoid common procedural and evidentiary failures.